| Jun 25 |
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
|
| Jun 24 |
7 Biotech Stocks to Buy on the Dip: June 2024
|
| Jun 24 |
Harmony wins Wakix label extension to include sleepiness in pediatric patients
|
| Jun 24 |
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY
|
| Jun 21 |
Harmony Bio gains as Citi starts at Buy on risk-reward setup
|
| Jun 21 |
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
|
| Jun 5 |
Harmony releases promising phase 2 results of pitolisant for myotonic dystrophy
|
| Jun 5 |
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1
|
| May 28 |
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE
|
